Emer O Hanrahan

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:2113-22. 2006
  2. ncbi request reprint Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma
    Emer O Hanrahan
    Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 10, Houston, TX 77030, USA
    J Clin Oncol 25:4952-60. 2007
  3. doi request reprint A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck
    Emer O Hanrahan
    Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Am J Clin Oncol 32:274-9. 2009
  4. pmc Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer
    Emer O Hanrahan
    University of Texas M D, Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:193-201. 2010
  5. doi request reprint Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer
    Merih Guray Durak
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Breast J 17:462-9. 2011
  6. pmc High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 27:5700-6. 2009
  7. doi request reprint Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer
    Emer O Hanrahan
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 15:3600-9. 2009
  8. ncbi request reprint Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer
    Emer O Hanrahan
    Departments of Thoracic Head and Neck Medical Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:s4617-22. 2007
  9. ncbi request reprint Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials
    Emer O Hanrahan
    Department of Breast Medical Oncology, Unit 1354, UT MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230 1439, USA
    Expert Opin Pharmacother 6:1477-91. 2005
  10. ncbi request reprint Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 104:1158-71. 2005

Detail Information

Publications12

  1. ncbi request reprint Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:2113-22. 2006
    ..Node-negative breast cancers that are < or = 1 cm are stage T1a,bN0M0. Controversy surrounds the prognosis of these patients with locoregional therapy only and the need for adjuvant systemic therapy...
  2. ncbi request reprint Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma
    Emer O Hanrahan
    Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 10, Houston, TX 77030, USA
    J Clin Oncol 25:4952-60. 2007
    ....
  3. doi request reprint A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck
    Emer O Hanrahan
    Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Am J Clin Oncol 32:274-9. 2009
    ..A phase II study of lonafarnib was conducted to determine its efficacy and safety in patients with recurrent, platinum-refractory SCCHN...
  4. pmc Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer
    Emer O Hanrahan
    University of Texas M D, Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:193-201. 2010
    ..It is unknown whether chemotherapy or VEGFR inhibitor/chemotherapy combinations induce changes in these or other cytokines and angiogenic factors (CAFs) and whether such changes could be markers of benefit...
  5. doi request reprint Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer
    Merih Guray Durak
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Breast J 17:462-9. 2011
    ..Age at diagnosis and associated FCC are significant factors in predicting recurrence in patients with T1a,bN0 IBC. Adjuvant systemic therapy should be discussed with and considered for young patients with T1a,bN0 IBC...
  6. pmc High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 27:5700-6. 2009
    ..To evaluate the risk of recurrence in women diagnosed with T1a and T1b, node-negative, human epidermal growth factor receptor 2 (HER2) -positive breast cancer...
  7. doi request reprint Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer
    Emer O Hanrahan
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 15:3600-9. 2009
    ..In study 7, vandetanib monotherapy was inferior to carboplatin-paclitaxel. We performed an exploratory retrospective analysis of the relationship between baseline circulating VEGF concentrations and PFS...
  8. ncbi request reprint Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer
    Emer O Hanrahan
    Departments of Thoracic Head and Neck Medical Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:s4617-22. 2007
    ....
  9. ncbi request reprint Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials
    Emer O Hanrahan
    Department of Breast Medical Oncology, Unit 1354, UT MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230 1439, USA
    Expert Opin Pharmacother 6:1477-91. 2005
    ....
  10. ncbi request reprint Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 104:1158-71. 2005
    ..An analysis of prognostic factors for these patients also is presented...
  11. ncbi request reprint Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 106:2327-36. 2006
    ..After a median follow-up of 6.5 years, no significant differences were observed in recurrence-free survival (RFS) or overall survival (OS) between the 2 arms. This report updates the survival analyses...
  12. ncbi request reprint Non-Hodgkin lymphoma: an update
    Bryan T Hennessy
    Department of Medical Oncology, St James Hospital, Dublin, Ireland
    Lancet Oncol 5:341-53. 2004
    ..Here, we review advances in the treatment of NHL that have occurred over the past 10 years...